VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. San Miguel on Pembrolizumab With Lenalidomide/ Dexamethasone in Multiple Myeloma

Jesus San Miguel, MD, PhD
Published: Tuesday, Dec 08, 2015



Jesus San Miguel, MD, PhD, professor of Hematology, medical director of the Clínica Universidad de Navarra, Universidad de Navarra, Pamplona, Spain, discusses the Keynote-023 study, which examined pembrolizumab in combination with lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma.

This open-label, phase I, multicenter, nonrandomized, dose-escalation trial evaluated the safety, tolerability, and efficacy of pembrolizumab in combination with lenalidomide and low-dose dexamethasone in these patients, who were heavily pretreated with more than three prior lines of therapy, San Miguel says. More than 95% of patients were treated with lenalidomide and bortezomib, 25% previously received carfilzomib and pomalidomide; 80% of patients underwent autologous stem cell transplantation, and 75% of patients were lenalidomide-refractory.

Researchers aimed to create an immune effect to enhance the capacity of the immune system to control tumor cells by adding pembrolizumabto the doublet, San Miguel explains. This triplet therapy was associated with a tolerable safety profile, but San Miguel cautions the data is preliminary.

<<< View more from the 2015 ASH Annual Meeting



Jesus San Miguel, MD, PhD, professor of Hematology, medical director of the Clínica Universidad de Navarra, Universidad de Navarra, Pamplona, Spain, discusses the Keynote-023 study, which examined pembrolizumab in combination with lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma.

This open-label, phase I, multicenter, nonrandomized, dose-escalation trial evaluated the safety, tolerability, and efficacy of pembrolizumab in combination with lenalidomide and low-dose dexamethasone in these patients, who were heavily pretreated with more than three prior lines of therapy, San Miguel says. More than 95% of patients were treated with lenalidomide and bortezomib, 25% previously received carfilzomib and pomalidomide; 80% of patients underwent autologous stem cell transplantation, and 75% of patients were lenalidomide-refractory.

Researchers aimed to create an immune effect to enhance the capacity of the immune system to control tumor cells by adding pembrolizumabto the doublet, San Miguel explains. This triplet therapy was associated with a tolerable safety profile, but San Miguel cautions the data is preliminary.

<<< View more from the 2015 ASH Annual Meeting


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x